The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).
 
Vineeth Tatineni
No Relationships to Disclose
 
Patrick Joseph O'Shea
No Relationships to Disclose
 
Yasmeen Rauf
No Relationships to Disclose
 
Xuefei Jia
No Relationships to Disclose
 
Erin Sennett Murphy
No Relationships to Disclose
 
Samuel T. Chao
Stock and Other Ownership Interests - Incyte (I)
Honoraria - Varian Medical Systems
Consulting or Advisory Role - Blue Earth Diagnostics
 
John H. Suh
Consulting or Advisory Role - Novocure; Philips, Inc.
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Abbvie; Apollomics; Bayer; Celularity; Flatiron Health; FORMA Therapeutics; GlaxoSmithKline; InSightec; KIYATEC; Novocure; Nuvation Bio; Tocagen; Varian Medical Systems
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)